Top 6 Dominating Key Players in Minimally Invasive Glaucoma Surgery (MIGS) Devices Market

The global minimally invasive glaucoma surgery (MIGS) devices market was valued at $144 million in 2016, and is projected to reach $912 million by 2023, growing at a CAGR of 30.1% from 2017 to 2023. The glaucoma in conjunction with cataract surgery segment accounted for three-fifths share of the market in 2016.

The key players operating in the market adopted product launch as one of their key developmental strategies.

Top Dominating Key Players:

  • Alcon Inc. (Novartis)
  • Ellex Medical Lasers Ltd.
  • Glaukos Corporation
  • Allergan Plc
  • Santen Pharmaceutical Co., Ltd.

Download sample PDF:

Rise in incidence of glaucoma across the globe, reoccurrence of glaucoma along with other eye disorders, and increase in preference for ab interno approach for the treatment of glaucoma propels the market growth. Geriatric population is prone to glaucoma such as mild to moderate glaucoma conditions, primary angle-closure glaucoma, and secondary angle-closure glaucoma, which is set to drive the growth of this market. Ineffective drug delivery witnessed in the glaucoma medication has propelled the transition of glaucoma treatment from medication to minimally invasive glaucoma surgery (MIGS) devices, thereby augmenting the market growth.

Minimally invasive glaucoma surgery (MIGS) devices are employed in the treatment of glaucoma to provide a safer and less invasive means of reducing intraocular pressure (IOP) as compared to conventional glaucoma surgery devices. MIGS devices are anticipated to become a preferred surgical modality in near future for the treatment of glaucoma as it reduces dependency on topical medications as well as gets rid of complications associated to traditional procedures. MIGS devices are most commonly employed in combined cataract surgeries through phacoemulsification. In addition, two prime approaches of IOP reduction by MIGS involve increase in trabecular outflow through bypassing the juxtacanalicular trabecular meshwork (TM), and rise in uveoscleral outflow via suprachoroidal pathways. These two approaches are most commonly used in the treatment of glaucoma as these approaches can reduce the IOP in eyes effectively while reducing post-operative complications.

Access Full Summary at :

Top Impacting Factors:

Increase in focus on developing combination surgeries for treatment of glaucoma, high prevalence of open-angle glaucoma, and rapid rise in geriatric population are anticipated to drive the growth of the minimally invasive glaucoma surgery (MIGS) devices market. In addition, increase in the changing demographics leading to obesity, diabetes, and varied eye disorders supplement the market growth. However, dearth of skilled professionals to perform minimally invasive glaucoma surgeries efficiently and high cost of the MIGS device hamper the market growth. Conversely, surge in investment by manufacturers in the emerging economies and rise in initiatives to reduce the burden of glaucoma globally are anticipated to offer lucrative opportunities for market expansion.

The trabecular meshwork target dominated the global MIGS devices market accounting for half of the total market share in 2016, and is set to maintain the dominance throughout the forecast period. At present, there are a few MIGS devices used to treat glaucoma by targeting the TM, namely, Trabectome, iStent, Hydrus, gonioscopy-assisted transluminal trabeculotomy (GATT), and excimer laser trabeculotomy (ELT). Extensive use of aforementioned products in the treatment of glaucoma contributed to the dominance of trabecular meshwork segment in the global MIGS devices market. Whereas, suprachoroidal space target is anticipated to grow at the fastest pace, registering a CAGR of 33.7% from 2017-2023.

Make purchase enquiry:

Key Findings of the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market:

• The MIGS stents generated the highest revenue in 2016, and is anticipated to do so throughout the forecast period, registering a CAGR of 27.1% from 2017 to 2023.

• Eye hospitals dominated the market, accounting for maximum share in 2016 and is expected to witness a CAGR of 26.3% from 2017 to 2023.

• North America dominated the global minimally invasive glaucoma surgery (MIGS) market, accounting for maximum share in 2016 and is expected to retain the same trend during 2017 to 2023.

• The MIGS shunts product segment is expected to witness the highest growth rate during the forecast period.

• Japan accounted for one-fourth share of the Asia-Pacific minimally invasive glaucoma surgery (MIGS) devices market in 2016.

Asia-Pacific witnessed highest growth rate for the minimally invasive glaucoma surgery (MIGS) devices market throughout the forecast period, owing to high population density and increase in geriatric population. In addition, rise in incidence of conditions such as moderate glaucoma and open-angle glaucoma in India and China boosts the market growth.


Shriram Dighe
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
[email protected]


Posted by on Friday August 10 2018, 4:45 PM EDT. All trademarks acknowledged. Filed under Medical Devices. Comments and Trackbacks closed. Follow responses: RSS 2.0

Comments are closed

News Categories

Featured Press Releases

Latest News

Log in